Do analysts prefer ALVR or LFVN?

Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts clearly believe Lifevantage is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, ALVR or LFVN?

Lifevantage has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Lifevantage $228.53M 0.36 $9.81M $0.45 14.51

Is ALVR or LFVN more profitable?

Lifevantage has a net margin of 2.94% compared to AlloVir's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Lifevantage 2.94% 23.89% 12.47%

Do analysts rate TELO or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, TELO or ALVR?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is TELO or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% AlloVir N/A -71.03% -61.27%

Do analysts rate ALVR or ENLV?

Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,792.86%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, ALVR or ENLV?

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is ALVR or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% Enlivex Therapeutics N/A 248.08% 206.39%

Do analysts recommend GANX or ALVR?

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Gain Therapeutics is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GANX or ALVR?

Gain Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gain Therapeutics N/A N/A -$20.16M -$0.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is GANX or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% AlloVir N/A -71.03% -61.27%

Do analysts rate SPRO or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

AlloVir (ALVR) Competitors

$3.73 -0.19 (-4.85%)

As of 07/24/2026

Compare

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

Should you buy AlloVir stock or one of its competitors? MarketBeat compares AlloVir with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AlloVir include Lifevantage (LFVN), Telomir Pharmaceuticals (TELO), Enlivex Therapeutics (ENLV), Gain Therapeutics (GANX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to Lifevantage?

AlloVir (NASDAQ:ALVR) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Lifevantage has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 35.3% of Lifevantage shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 22.0% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lifevantage has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Lifevantage	$228.53M	0.36	$9.81M	$0.45	14.51

In the previous week, Lifevantage had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Lifevantage and 0 mentions for AlloVir. Lifevantage's average media sentiment score of 1.47 beat AlloVir's score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Lifevantage	Positive

Lifevantage has a net margin of 2.94% compared to AlloVir's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Lifevantage	2.94%	23.89%	12.47%

Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts clearly believe Lifevantage is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifevantage beats AlloVir on 12 of the 14 factors compared between the two stocks.

How does AlloVir compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Telomir Pharmaceuticals has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 0 mentions for AlloVir. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat AlloVir's score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Positive
AlloVir	Neutral

66.1% of AlloVir shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

AlloVir's return on equity of -71.03% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
AlloVir	N/A	-71.03%	-61.27%

Summary

Telomir Pharmaceuticals and AlloVir tied by winning 6 of the 12 factors compared between the two stocks.

How does AlloVir compare to Enlivex Therapeutics?

AlloVir (NASDAQ:ALVR) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 5,792.86%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Enlivex Therapeutics had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Enlivex Therapeutics and 0 mentions for AlloVir. Enlivex Therapeutics' average media sentiment score of 0.78 beat AlloVir's score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Enlivex Therapeutics	Positive

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Enlivex Therapeutics' return on equity of 248.08% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Enlivex Therapeutics	N/A	248.08%	206.39%

Summary

Enlivex Therapeutics beats AlloVir on 11 of the 14 factors compared between the two stocks.

How does AlloVir compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

AlloVir's return on equity of -71.03% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
AlloVir	N/A	-71.03%	-61.27%

Gain Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	N/A	N/A	-$20.16M	-$0.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gain Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 328.57%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Gain Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Gain Therapeutics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Gain Therapeutics and 0 mentions for AlloVir. Gain Therapeutics' average media sentiment score of 1.15 beat AlloVir's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Positive
AlloVir	Neutral

Gain Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Summary

Gain Therapeutics beats AlloVir on 7 of the 13 factors compared between the two stocks.

How does AlloVir compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spero Therapeutics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.03	$8.57M	$0.24	4.96
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, Spero Therapeutics had 3 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Spero Therapeutics and 0 mentions for AlloVir. Spero Therapeutics' average media sentiment score of 0.93 beat AlloVir's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Positive
AlloVir	Neutral

Spero Therapeutics has a net margin of 24.90% compared to AlloVir's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
AlloVir	N/A	-71.03%	-61.27%

Spero Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Summary

Spero Therapeutics beats AlloVir on 11 of the 13 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.81M	$357.18M	$6.87B	$12.26B
Dividend Yield	N/A	N/A	2.67%	9.79%
P/E Ratio	-0.18	N/A	27.14	23.64
Price / Sales	N/A	228.84	517.08	89.45
Price / Cash	N/A	22.44	50.54	59.64
Price / Book	0.13	4.88	10.28	6.07
Net Income	-$190.42M	-$141.03M	$3.60B	$331.99M
7 Day Performance	-14.84%	-1.69%	-1.27%	-0.63%
1 Month Performance	-15.23%	0.21%	-0.37%	-2.00%
1 Year Performance	31.34%	39.82%	18.30%	13.62%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$3.73 -4.8%	N/A	+46.9%	$18.81M	N/A	N/A	110	High Trading Volume
LFVN Lifevantage	2.7357 of 5 stars	$6.28 -1.9%	$5.00 -20.4%	-53.3%	$79.25M	$228.53M	13.96	260	Positive News Gap Down
TELO Telomir Pharmaceuticals	0.4518 of 5 stars	$1.15 +6.0%	N/A	-49.8%	$78.75M	N/A	N/A	1
ENLV Enlivex Therapeutics	3.1993 of 5 stars	$4.60 -2.7%	$247.50 +5,280.4%	-75.5%	$77.85M	N/A	N/A	70	News Coverage Analyst Upgrade Short Interest Decrease
GANX Gain Therapeutics	2.9102 of 5 stars	$1.83 -0.8%	$7.50 +311.0%	+4.2%	$77.84M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

How does AlloVir compare to Lifevantage?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Summary

How does AlloVir compare to Enlivex Therapeutics?

Summary

How does AlloVir compare to Gain Therapeutics?

Summary

How does AlloVir compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. LFVN, TELO, ENLV, GANX, and SPRO

How does AlloVir compare to Lifevantage?

Which has more risk & volatility, ALVR or LFVN?

Do insiders & institutionals hold more shares of ALVR or LFVN?

Which has preferable valuation & earnings, ALVR or LFVN?

Does the media prefer ALVR or LFVN?

Is ALVR or LFVN more profitable?

Do analysts prefer ALVR or LFVN?

Summary

How does AlloVir compare to Telomir Pharmaceuticals?

Which has higher earnings and valuation, TELO or ALVR?

Which has more volatility & risk, TELO or ALVR?

Does the media favor TELO or ALVR?

Do institutionals & insiders believe in TELO or ALVR?

Do analysts rate TELO or ALVR?

Is TELO or ALVR more profitable?

Summary

How does AlloVir compare to Enlivex Therapeutics?

Do insiders & institutionals believe in ALVR or ENLV?

Which has more risk and volatility, ALVR or ENLV?

Do analysts rate ALVR or ENLV?

Does the media prefer ALVR or ENLV?

Which has better valuation and earnings, ALVR or ENLV?

Is ALVR or ENLV more profitable?

Summary

How does AlloVir compare to Gain Therapeutics?

Is GANX or ALVR more profitable?

Which has better valuation & earnings, GANX or ALVR?

Do insiders & institutionals believe in GANX or ALVR?

Do analysts recommend GANX or ALVR?

Does the media refer more to GANX or ALVR?

Which has more volatility & risk, GANX or ALVR?

Summary

How does AlloVir compare to Spero Therapeutics?

Do institutionals & insiders believe in SPRO or ALVR?

Do analysts rate SPRO or ALVR?

Which has preferable valuation & earnings, SPRO or ALVR?

Does the media refer more to SPRO or ALVR?

Is SPRO or ALVR more profitable?

Which has more risk and volatility, SPRO or ALVR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools